NR1H4 and metabolic dysfunction-associated steatotic liver disease: Obeticholic acid, an FXR agonist, is approved as a second-line therapy for primary biliary cholangitis 255, and both it and other FXR agonists, such as vonafexor are being investigated as treatments for MASLD fibrosis 256.